Home LiteratureArticle Details
PMID: 15711642 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

The Journal of clinical investigation ·Vol. 115 ·No. 3 ·2005-03-00 ·Pages 755-64

Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, Murphy EJ, Koduru P, Ferrarini M, Zupo S, Cutrona G, Damle RN, Wasil T, Rai KR, Hellerstein MK, Chiorazzi N

Abstract

Due to its relatively slow clinical progression, B cell chronic lymphocytic leukemia (B-CLL) is classically described as a disease of accumulation rather than proliferation. However, evidence for various forms of clonal evolution suggests that B-CLL clones may be more dynamic than previously assumed. We used a nonradioactive, stable isotopic labeling method to measure B-CLL cell kinetics in vivo. Nineteen patients drank an aliquot of deuterated water (2H2O) daily for 84 days, and 2H incorporation into the deoxyribose moiety of DNA of newly divided B-CLL cells was measured by gas chromatography/mass spectrometry, during and after the labeling period. Birth rates were calculated from the kinetic profiles. Death rates were defined as the difference between calculated birth and growth rates. These analyses demonstrated that the leukemic cells of each patient had definable and often substantial birth rates, varying from 0.1% to greater than 1.0% of the entire clone per day. Those patients with birth rates greater than 0.35% per day were much more likely to exhibit active or to develop progressive disease than those with lower birth rates Thus, B-CLL is not a static disease that results simply from accumulation of long-lived lymphocytes. Rather, it is a dynamic process composed also of cells that proliferate and die, often at appreciable levels. The extent to which this turnover occurs has not been previously appreciated. A correlation between birth rates and disease activity and progression appears to exist, which may help identify patients at risk for worsening disease in advance of clinical deterioration.

MeSH Terms
Aged B-Lymphocytes/cytology,metabolism Cell Proliferation Cell Separation DNA/metabolism Deuterium/metabolism Disease Progression Female Follow-Up Studies Humans Leukemia, Lymphocytic, Chronic, B-Cell/genetics,metabolism,pathology,physiopathology Male Middle Aged Models, Biological Water/chemistry
Chemicals
Water DNA Deuterium
Authors & Affiliations
16 authors, click to expand affiliations / ORCID
Messmer Bradley T
Institute for Medical Research, North Shore-LIJ Research Institute, Manhasset, New York 11030, USA
Messmer Davorka
Allen Steven L
Kolitz Jonathan E
Kudalkar Prasad
Cesar Denise
Murphy Elizabeth J
Koduru Prasad
Ferrarini Manlio
Zupo Simona
Cutrona Giovanna
Damle Rajendra N
Wasil Tarun
Rai Kanti R
Hellerstein Marc K
Chiorazzi Nicholas
References (36)
36 references, click to expand
  1. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms.
    Adv Cancer Res. 2000;79:157-73 PMID: 10818680
  2. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
    Blood. 1999 Sep 15;94(6):1848-54 PMID: 10477713
  3. The pathologist's view point. Part I--indolent lymphomas.
    Haematologica. 2000 Dec;85(12):1291-307 PMID: 11114137
  4. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.
    Blood. 2001 May 1;97(9):2777-83 PMID: 11313271
  5. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.
    Blood. 2002 Feb 1;99(3):1023-9 PMID: 11807008
  6. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.
    Br J Haematol. 2001 Dec;115(4):854-61 PMID: 11843819
  7. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.
    Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3854-9 PMID: 11891278
  8. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.
    Blood. 2002 Aug 15;100(4):1410-6 PMID: 12149225
  9. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
    Blood. 2002 Dec 15;100(13):4609-14 PMID: 12393534
  10. Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA.
    Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15345-50 PMID: 12424339
  11. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression.
    Blood. 2003 Feb 15;101(4):1262-9 PMID: 12406914
  12. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
    N Engl J Med. 2003 May 1;348(18):1764-75 PMID: 12724482
  13. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
    Blood. 2003 Jun 15;101(12):4944-51 PMID: 12595313
  14. Chronic lymphocytic leukemia--an accumulative disease of immunolgically incompetent lymphocytes.
    Blood. 1967 Apr;29(4):Suppl:566-84 PMID: 6022294
  15. Studies of leukocyte kinetics in chronic lymphocytic leukemia.
    Blood. 1968 Mar;31(3):277-91 PMID: 5640626
  16. Lymphocyte kinetics in chronic lymphocytic leukaemia (CLL) studied by ECIB.
    Br J Haematol. 1969 Oct;17(4):408 PMID: 4899589
  17. Kinetics of lymphocytes in chronic lymphocytic leukemia. I. Equilibrium between blood and a "readily accessible pool".
    Blood. 1973 Mar;41(3):425-38 PMID: 4690140
  18. Kinetics of lymphocytes in chronic lymphocytic leukemia: studies using continuous 3H-thymidine infusion in two patients.
    Blood. 1973 Oct;42(4):623-36 PMID: 4778708
  19. Cell kinetics in chronic lymphocytic leukaemia (CLL).
    Clin Haematol. 1977 Feb;6(1):159-67 PMID: 334407
  20. Studies in chronic lymphocytic leukaemia. The kinetics of 51Cr-labelled lymphocytes.
    Scand J Haematol. 1978 Jan;20(1):37-51 PMID: 580123
  21. Biochemical characteristics of chronic lymphocytic leukaemia. Glucocorticoid receptors, B and T lymphocyte surface markers, concanavalin A-induced agglutination and thymidine incorporation.
    Scand J Haematol. 1978 Nov;21(5):379-89 PMID: 310576
  22. Correlation of total body potassium and leukemic cell mass in patients with chronic lymphocytic leukemia.
    Blood. 1979 Apr;53(4):594-603 PMID: 106861
  23. 3H-thymidine uptake in chronic lymphocytic leukaemia cells.
    Scand J Haematol. 1980 Feb;24(2):169-73 PMID: 7375818
  24. Chronic lymphocytic leukemia: a proliferative or accumulative disorder?
    Leuk Res. 1983;7(1):1-10 PMID: 6834882
  25. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance.
    Br J Haematol. 1986 Mar;62(3):567-75 PMID: 3954968
  26. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia.
    Cancer. 1987 Dec 1;60(11):2712-6 PMID: 3677006
  27. Metabolism and action of purine nucleoside analogs.
    Pharmacol Ther. 1991;49(3):239-68 PMID: 1675805
  28. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL.
    Blood. 1991 Oct 15;78(8):1901-14 PMID: 1912574
  29. Evolution of leukemic heterogeneity of human B-CLL lymphocytes between and within patients.
    Curr Top Microbiol Immunol. 1992;182:303-11 PMID: 1490369
  30. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study.
    Histopathology. 1994 May;24(5):445-51 PMID: 8088716
  31. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
    Blood. 1996 Jun 15;87(12):4990-7 PMID: 8652811
  32. Measurement of cell proliferation by labeling of DNA with stable isotope-labeled glucose: studies in vitro, in animals, and in humans.
    Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):708-13 PMID: 9435257
  33. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.
    J Clin Invest. 1998 Oct 15;102(8):1515-25 PMID: 9788964
  34. B-cell chronic lymphocytic leukemia: a bird of a different feather.
    J Clin Oncol. 1999 Jan;17(1):399-408 PMID: 10458259
  35. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
    Blood. 1999 Sep 15;94(6):1840-7 PMID: 10477712
  36. Genomic aberrations and survival in chronic lymphocytic leukemia.
    N Engl J Med. 2000 Dec 28;343(26):1910-6 PMID: 11136261
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
2005-03-00
Pages
755-64
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC548318
Subset
IM
Grants
NCI NIH HHS · R01 CA087956 · United States
NCI NIH HHS · R01 CA81554 · United States
NCRR NIH HHS · M01 RR018535 · United States
NCI NIH HHS · R01 CA081554 · United States
NCI NIH HHS · R01 CA87956 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com